Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction
Su S, Heston W, Perroti M, Cookson M, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair W. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997, 49: 95-101. PMID: 9123743, DOI: 10.1016/s0090-4295(97)00175-1.Peer-Reviewed Original ResearchConceptsProstatic specific membrane antigenAndrogen deprivation therapyNeoadjuvant androgen deprivation therapyADT groupReverse transcription-polymerase chain reactionDeprivation therapyTranscription-polymerase chain reactionControl groupProstatic cellsTumor cellsPT2 patientsPT3 patientsSystemic diseasePolymerase chain reactionEffectiveness of ADTMemorial Sloan-Kettering Cancer CenterSerum PSA valuesProstate cancer patientsChain reactionHigher positive rateProstatic epithelial cellsPT3 lesionsControl patientsExtraprostatic diseaseAdditional patientsClinical significance of repeat sextant biopsies in prostate cancer patients
Stroumbakis N, Cookson M, Reuter V, Fair W. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997, 49: 113-118. PMID: 9123730, DOI: 10.1016/s0090-4295(97)00178-7.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsBiopsy, NeedleHumansMaleProspective StudiesProstatectomyProstatic NeoplasmsSelection BiasSensitivity and SpecificityUltrasonographyConceptsProstate-specific antigenOrgan-confined rateMargin-positive rateProstate cancerPSA densityRebiopsy resultsRepeat biopsySextant biopsyFinal surgical margin statusRandom systematic core biopsiesGreater prostate volumeNegative repeat biopsyAndrogen deprivation therapySurgical margin statusLower clinical stageProstate cancer patientsSignificant prostate cancerBiopsy-proven prostate cancerDeprivation therapyPositive rebiopsyConsecutive patientsInitial biopsyMargin statusProstate volumeT stageThe indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients